KRYS — Krystal Biotech, Inc.
$305.23
$-0.45 (-0.15%)
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Market Cap
$9.05B
Forward P/E
33.1x
52-Week Range
N/A
KRYS Price History
Revenue vs. Net Income
$389M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$189M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
13.1%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
11.7x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
3.1%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+0.7%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
